Comment from Association for Accessible Medicines (AAM)

Summary: The Association for Accessible Medicines (AAM), representing generic and biosimilar pharmaceutical manufacturers, supports the draft guidance on using AI in regulatory decision-making. They suggest specific improvements to enhance the guidance's utility, including adding more technical examples, clarifying transparency vs. intellectual property protections, and refining requirements for performance metrics and confidence intervals.